This paper discusses the specifics of planning in multiagent environments. It presents the formal framework MAPL (“maple”) for describing multiagent planning domains. MAPL allows to describe both qualitative and quantitative temporal relations among events, thus subsuming the temporal models of both PDDL 2.1 and POP. Other features are different levels of control over actions, modeling of agent...

For a long time, the role of the environment has been underestimated in multiagent systems research. Originating from research on behavior-based agents and situated multiagent systems, the importance of the environment is now gradually being accepted in the multiagent system community in general. In this paper, we elaborate on the role of environments in multiagent systems. We present a model f...

Multiagent learning is a promising direction of the modern and future research in the context of intelligent systems. While the single-agent case has been well studied in the last two decades, the multiagent case has not been broadly studied due to its complexity. When several autonomous agents learn and act simultaneously, the environment becomes strictly unpredictable and all assumptions that...

Multiagent systems present many challenging, real-world problems to artificial intelligence. Because it is difficult to engineer the behaviors of multiple cooperating agents by hand, multiagent learning has become a popular approach to their design. While there are a variety of traditional approaches to multiagent learning, many suffer from increased computational costs for large teams and the ...

BACKGROUND Nodal peripheral T-cell lymphomas (PTCLs) are infrequent subtypes of non-Hodgkin's lymphomas. The WHO classification recognizes three subgroups of nodal PTCL: peripheral T-cell lymphoma not otherwise specified (PTCL, NOS), anaplastic large cell lymphoma (ALCL) and angioimmunoblastic lymphoma (AIL). The clinical course is aggressive and despite multiagent chemotherapy, the median surv...

BACKGROUND Many new agents are currently in trial in melanoma. It remains unclear, however, what the benefit of a given therapy may be since information on progression-free and overall survival of untreated patients is limited. Since few trials in melanoma have had a non-treated cohort, it remains unclear what survival can be expected in patients who are not treated with chemotherapy. METHODS...